Circulating tumor DNA (ctDNA) has been approved by the Committee for Medicinal Products for Human Use of the European Medicines Agency [21] to assess EGFR mutation status in patients with NSCLC for whom it is not possible to obtain a tumor sample. This evidence concerns the gene EGFR and non-small cell lung carcinoma.